Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
228.41 USD   -1.11%
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biotech stocks pin bounce back hopes on M&A boost

08/12/2022 | 10:00am EDT
FILE PHOTO: Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana

(Reuters) - Plunging valuations have made biotech companies tempting acquisition targets for cash-rich Big Pharma and a flurry of deals is just what the battered sector needs to turn a corner.

Pfizer's $5.4 billion acquisition of Global Blood Therapeutics, which was announced on Monday, is the fourth deal in the sector since the pharma giant bought Biohaven for $11.6 billion in May, adding to optimism that large drugmakers are back in the market to pick up cheaper firms.

Industry experts predict biotech firms that are closer to getting their product to market or already have a drug approved are likely to become M&A targets for large drugmakers, some of whom are staring at patent expirations of their cash cow drugs.

GRAPHIC: Biotech M&A since Pfizer's Biohaven deal (

)

"(There have been) acquisitions of companies that have late-stage assets and also the theme of large-cap companies keeping an eye on mid-caps approaching blockbusters," RBC Capital Markets analyst Gregory Renza said. "So needing to replenish portfolios and finding companies like those are key."

Biotech company stocks have been battered in the past few months as investors booked profits after a sharp rise in valuations in 2021, with the rout exacerbated by a dearth of large deals and lack of positive data from clinical trials.

The Nasdaq Biotechnology index fell nearly 28% in the year till the Pfizer-Biohaven deal was announced in May. Since then, the index is up over 18%.

The SPDR S&P Biotech ETF is also up 34% in that period, while iShares Biotechnology ETF is up about 19%.

GRAPHIC: Changes in the Nasdaq Biotech index and biotech ETFs (https://fingfx.thomsonreuters.com/gfx/mkt/zdvxozxyxpx/SnP%20Biotech%20ETF%20NBI%20index.JPG)

"Pfizer's move put boards across big pharma on notice that if you're not in the market buying these companies while they're cheap, your competitors will," Thomas Hayes, chairman and managing member of Great Hill Capital in New York, said.

Still, not all analysts are convinced the bottom has been reached for these stocks and believe there is still a long way to go for biotechs, especially considering the risky nature of the business.

"I don't think we'll get back to 2021 (funding) levels ... but we're seeing a nice virtuous cycle of good data, more capital entering the space and more M&A," Sean Sun, portfolio manager at Thornburg Investment Management, said.

Sentiment around the beaten-down sector has improved in the past month.

About $86 million was poured into iShares Biotechnology ETF in July, compared with $7 million in June, following outflows in the two preceding months, according to Refinitiv Lipper data.

The number of stocks in the biotech index that trade below their cash level has also reduced. One of four biotech stocks that are part of the index now trade below their cash level, from one of three in the last week of June, Refinitiv data showed.

"The fundamentals are strong as ever, the valuations have corrected and the acquirers have a boatload of money," said Lee Brown, global healthcare leader for investment research firm Third Bridge. "So it's sort of like - let's party."

(Additional reporting by Medha Singh; Editing by Ankur Banerjee and Shounak Dasgupta)

By Amruta Khandekar and Leroy Leo


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -1.11% 228.41 Delayed Quote.1.53%
CHEMOCENTRYX, INC. -0.04% 51.66 Delayed Quote.41.88%
GLOBAL BLOOD THERAPEUTICS, INC. -0.06% 68.07 Delayed Quote.132.56%
GSK PLC 0.17% 1318.8 Delayed Quote.-19.94%
NASDAQ COMPOSITE -2.84% 10737.51 Real-time Quote.-29.36%
PAX DOLLAR (USDP/USD) -0.20% 0.999 End-of-day quote.-0.09%
PFIZER, INC. -0.61% 44.16 Delayed Quote.-25.22%
All news about AMGEN INC.
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/21EU approves AstraZeneca-Amgen treatment for severe asthma
RE
09/19Novartis' Biosimilar for Osteoporosis Drug Xgeva Matches Reference Therapy in Safety, E..
MT
09/16Amgen : Is Ready to Meet Growing Demand for Innovative Medicines, Says Bradway in Bloomber..
PU
09/15Consumer group says drugmakers abuse U.S. patent system to keep prices high
RE
09/15Transcript : Amgen Inc. Presents at BofA Securities Global Healthcare Confere..
CI
09/13Asthma Peak Week : What You Need to Know About Indoor Air Pollution
PU
09/13Transcript : Amgen Inc. Presents at Morgan Stanley 20th Annual Global Healthc..
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 146 M - -
Net income 2022 6 293 M - -
Net Debt 2022 27 027 M - -
P/E ratio 2022 19,4x
Yield 2022 3,40%
Capitalization 122 B 122 B -
EV / Sales 2022 5,71x
EV / Sales 2023 5,43x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 228,41 $
Average target price 249,81 $
Spread / Average Target 9,37%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.1.53%122 184
JOHNSON & JOHNSON-3.82%432 579
ELI LILLY AND COMPANY21.06%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.22%247 841